Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYB1904 in perennial allergic rhinitis
NCT07459452Phase 2Not yet recruiting
- Sponsor
- Jemincare
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ozureprubart in perennial allergic rhinitis (PAR), sponsored by Jemincare. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ozureprubart
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT07459452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459452.